DWA
RARX

Dorsey Wright & Associates’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History

Dorsey Wright & Associates’s Portfolio RARX Stock Details RARX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-722
Closed -$22K – 349
2019
Q2 		$22K Buy
722
+180
+33% +$4.12K 0.01% 146
2019
Q1 		$12K Sell
542
-537
-50% -$11.5K ﹤0.01% 161
2018
Q4 		$20K Buy
+1,079
New +$16.9K 0.01% 141

Other funds holding RARX

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Dorsey Wright & Associates's RARX Position: Q3 2019 in Review

Dorsey Wright & Associates sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q3 2019, closing a stake of 722 shares — an estimated $22K sold.

Dorsey Wright & Associates first reported a position in RARX in Q4 2018 and held it in 3 quarters. The position peaked at $22K in Q2 2019. 119 funds tracked by Wall St. Rank hold RARX as of Q3 2019.

  • Dorsey Wright & Associates reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q3 2019 after selling out during the quarter.
  • Dorsey Wright & Associates sold 722 Ra Pharmaceuticals, Inc. Common Stock shares in Q3 2019, an estimated $22K.
  • Dorsey Wright & Associates first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q4 2018 and held it in 3 quarters.
  • Dorsey Wright & Associates's Ra Pharmaceuticals, Inc. Common Stock position peaked at $22K in Q2 2019.
  • 119 funds tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q3 2019.

Based on Dorsey Wright & Associates's 13F filing for Q3 2019, filed 31 Oct 2019.